[go: up one dir, main page]

BG105933A - Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists - Google Patents

Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists

Info

Publication number
BG105933A
BG105933A BG105933A BG10593301A BG105933A BG 105933 A BG105933 A BG 105933A BG 105933 A BG105933 A BG 105933A BG 10593301 A BG10593301 A BG 10593301A BG 105933 A BG105933 A BG 105933A
Authority
BG
Bulgaria
Prior art keywords
compositions
methods
norcisapride
combination
receptor antagonists
Prior art date
Application number
BG105933A
Other languages
Bulgarian (bg)
English (en)
Inventor
Paul Rubin
Timothy Barberich
Original Assignee
Sepracor, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor, Inc filed Critical Sepracor, Inc
Publication of BG105933A publication Critical patent/BG105933A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG105933A 1999-03-02 2001-09-21 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists BG105933A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12239499P 1999-03-02 1999-03-02
PCT/US2000/005166 WO2000051583A2 (en) 1999-03-02 2000-03-01 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists

Publications (1)

Publication Number Publication Date
BG105933A true BG105933A (en) 2002-12-29

Family

ID=22402463

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105933A BG105933A (en) 1999-03-02 2001-09-21 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists

Country Status (23)

Country Link
US (3) US6353005B1 (zh)
EP (1) EP1156852A2 (zh)
JP (1) JP2002538103A (zh)
KR (1) KR20010108298A (zh)
CN (1) CN1364092A (zh)
AR (1) AR037065A1 (zh)
AU (1) AU780579B2 (zh)
BG (1) BG105933A (zh)
BR (1) BR0008687A (zh)
CA (1) CA2362501A1 (zh)
CO (1) CO5150232A1 (zh)
EA (1) EA200100936A1 (zh)
EE (1) EE200100458A (zh)
HR (1) HRP20010635A2 (zh)
HU (1) HUP0200298A3 (zh)
ID (1) ID30445A (zh)
IL (1) IL145162A0 (zh)
NO (1) NO20014230L (zh)
NZ (1) NZ513966A (zh)
PL (1) PL352579A1 (zh)
SK (1) SK12352001A3 (zh)
TR (3) TR200103130T2 (zh)
WO (1) WO2000051583A2 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US6663639B1 (en) * 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US7846180B2 (en) * 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
US6673792B1 (en) * 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
EP1536841A1 (en) * 2002-09-12 2005-06-08 The University of Chicago Monitoring and diagnosis of gastric emptying and gastroparesis
CA2542620A1 (en) * 2002-10-16 2004-04-29 Warren Stern Method of treating snoring and other obstructive breathing disorders
SE0203410D0 (sv) * 2002-11-18 2002-11-18 Astrazeneca Ab New use
CN100353946C (zh) * 2003-01-13 2007-12-12 戴诺吉药品有限公司 治疗功能性肠病的方法
MXPA05007379A (es) 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
EP1596838A2 (en) * 2003-02-11 2005-11-23 Torrent Pharmaceuticals Ltd Once a day orally administered pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
RS20050868A (sr) * 2003-05-27 2007-08-03 Altana Pharma Ag., Farmaceutske kombinacije inhibotora protonske pumpe i jedinjenje koje modifikuje gastrointestinalni motilitet
WO2005011678A1 (en) * 2003-07-31 2005-02-10 Altana Pharma Ag Method for reducing the volume of gastric refluxate
EP1663313A2 (en) * 2003-08-29 2006-06-07 Dynogen Pharmaceuticals Inc. Compositions useful for treating gastrointestinal motility disorders
WO2005074931A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations comprising (s) -pantoprazole
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
KR20070107016A (ko) * 2005-01-31 2007-11-06 노파르티스 아게 양성자 펌프 억제제에 의해 유발될 수 있는 위 배출 지연을치료하기 위한 5-ｈｔ4 효능제의 용도
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
KR101690942B1 (ko) * 2015-03-17 2016-12-29 전남대학교산학협력단 시토크롬 p450 효소전환기술을 이용하여 제조한 오메프라졸 대사체를 이용한 위궤양 치료용 조성물
WO2018215462A1 (en) * 2017-05-22 2018-11-29 Københavns Universitet Cic-2 - the molecular basis of cardiac arrhythmia

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5914460B2 (ja) 1978-12-27 1984-04-04 相互薬工株式会社 Ｈ↓２受容体「きつ」抗剤シメチジンの製造法
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
US4598123A (en) 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
SI8710091A8 (en) 1987-01-23 1996-06-30 Lek Tovarna Farmacevtskih Process for obtaining crystalline cimetadine (n-cyano-n'-methyl-n"- (2/(5-methyl-1h-imidazole-4-yl)methylthio/ethyl)-guanidine
IT1215344B (it) 1987-01-27 1990-02-08 Dessy S R L Ora Recordati Farm Procedimento per la preparazione di composti ad attivita' anti-ulcera.
JPH0623181B2 (ja) 1987-02-17 1994-03-30 三井石油化学工業株式会社 シアノグアニジン誘導体及びその製造法
JPH0623180B2 (ja) 1987-02-17 1994-03-30 三井石油化学工業株式会社 シアノグアニジン誘導体及びその製造法
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
ES2121984T3 (es) 1991-12-21 1998-12-16 Smithkline Beecham Plc Uso de antagonistas de 5-ht4 para la fabricacion de un medicamento para el tratamiento de la incontinencia urinaria.
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP1170010A3 (en) 1992-07-07 2004-05-19 Sepracor Inc. Method of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
WO1994001112A1 (en) 1992-07-07 1994-01-20 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
WO1995001803A1 (en) 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
US5502195A (en) 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5541335A (en) 1994-07-11 1996-07-30 Torcan Chemical Ltd. Process for preparing nizatidine
US5712293A (en) 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
NL1003622C2 (nl) 1996-07-17 1998-01-21 Inst Voor Agrotech Onderzoek Lijm op basis van zetmeel.
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
AU757077B2 (en) 1997-07-11 2003-01-30 Janssen Pharmaceutica N.V. (+)-norcisapride useful for 5-HT3 and 5-HT4 mediated disorders
IL140118A0 (en) * 1998-06-15 2002-02-10 Sepracor Inc Use of optically pure (+) norcisapride for treating apnea, bulimia and other disorders
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists

Also Published As

Publication number Publication date
US20020086880A1 (en) 2002-07-04
CA2362501A1 (en) 2000-09-08
US20030036500A1 (en) 2003-02-20
US6353005B1 (en) 2002-03-05
TR200103130T2 (tr) 2002-03-21
BR0008687A (pt) 2002-01-08
ID30445A (id) 2001-12-06
HUP0200298A3 (en) 2002-11-28
SK12352001A3 (sk) 2001-12-03
CO5150232A1 (es) 2002-04-29
KR20010108298A (ko) 2001-12-07
NZ513966A (en) 2001-09-28
HUP0200298A2 (en) 2002-06-29
IL145162A0 (en) 2002-06-30
AU3386200A (en) 2000-09-21
NO20014230D0 (no) 2001-08-31
JP2002538103A (ja) 2002-11-12
TR200201795T2 (tr) 2002-09-23
US6552045B2 (en) 2003-04-22
EA200100936A1 (ru) 2002-10-31
WO2000051583A3 (en) 2001-02-01
AU780579B2 (en) 2005-04-07
AR037065A1 (es) 2004-10-20
CN1364092A (zh) 2002-08-14
EE200100458A (et) 2002-12-16
NO20014230L (no) 2001-11-01
PL352579A1 (en) 2003-08-25
WO2000051583A2 (en) 2000-09-08
TR200201794T2 (tr) 2002-09-23
EP1156852A2 (en) 2001-11-28
HRP20010635A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
BG105933A (en) Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
BG105932A (en) Methods and compositions using (-)norcisapride in combination with proton pump inhibitors or h2 receptor antagonists
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
DK1054887T3 (da) Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister
LT2000123A (lt) Bifenilsulfonamidai kaip dvigubi angiotenzino ir endotelino receptorių antagonistai
MY134568A (en) Cb2 receptor agonists
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
DE60020962D1 (de) Ligande für metabotropische glutamat-rezeptoren
TR199802269T2 (xx) Endotelin resept�r antagonistleri olarak faydal� indol t�revleri.
TW200508226A (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
RO118870B1 (ro) Monometansulfonat de acid (e)-alfa-[2-n-butil-1-[(4-carboxifenil)metil]-1h-imidazol-5-il]metilen-2-tiofenpropionic, procedee de preparare şi compoziţii farmaceutice
EP1383919A4 (en) METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDE AS MACROPHAGE MIGRATION INHIBITION FACTOR RECEPTOR
DK1176963T3 (da) Anvendelse af dopamin-D3-receptorantagonister til fremstilling af lægemidler til behandling af nyrefunktionsforstyrrelser
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
NO20012194L (no) CRF-reseptorantagonister og tilhörende fremgangsmåter
DK1079843T3 (da) Anvendelse af a1beta1 integrinreceptorinhibitorer og TFG beta1 inhibitorer til behandling af nyresygdom
TW200507855A (en) Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
MY127120A (en) A1 adenosine receptor antagonists
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
BG105097A (en) Use of optically pure(-)norcisapride in the treatment of apnea, bulimia, and other disorders
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
NZ516209A (en) Indoloazepines as vasopressin receptor antagonists
WO2003105854A3 (en) Substituted dihydropyrimidines and dihydropyrimidinethiones as calcium channel blockers
SE0300988D0 (sv) New use